Cannabis Users Over 40 Have Bigger Brains and Faster Minds

26,000 brains. The cannabis users came out ahead.

For decades, the story about cannabis and the brain has been a warning. It shrinks your hippocampus. It kills brain cells. It makes you slower, foggier, less sharp. That narrative was built almost entirely on studies of adolescents and heavy users, and it shaped policy, public opinion, and a generation of parents' fears.

A 2026 University of Colorado study just complicated that story in ways nobody expected.

Researchers analyzed brain scans and cognitive testing data from over 26,000 adults aged 40 to 77 using the UK Biobank, one of the largest biomedical databases in the world. What they found: adults with a history of cannabis use had larger gray matter volumes in brain regions critical for memory, emotion, and motor learning. They processed information faster. Their brains looked different from non-users -- and not in the way the old narrative predicted.

This is not proof that cannabis makes your brain bigger. Correlation is not causation, and the researchers are the first to say so. But it is the largest study of its kind, and the findings demand a serious conversation about what cannabis actually does to the aging brain -- a conversation that rising above the stigma requires.

The Study: 26,000 Adults, One Surprising Pattern

The University of Colorado Anschutz Medical Campus used UK Biobank data covering adults aged 40 to 77 with a mean age of 54.5 years. They compared MRI brain imaging and standardized cognitive testing between cannabis users and non-users, focusing specifically on brain regions with high densities of CB1 receptors -- the primary receptors that THC interacts with.

The cannabis-using group showed larger gray matter volumes in the hippocampus, amygdala, and putamen. The hippocampus is the brain's memory center and one of the first regions to deteriorate in Alzheimer's disease. The amygdala processes emotions. The putamen handles motor learning and coordination. All three are regions that typically shrink with age.

On cognitive testing, cannabis users demonstrated faster processing speeds compared to non-users in the same age group. They performed better on tests measuring learning, memory, attention, and executive function.

Lead researcher Dr. Angela Guha said she was "surprised by the extent of the positive findings." The team took a deliberately nuanced approach, examining specific brain regions rather than looking at total brain volume, because total volume can mask regional differences that matter for specific cognitive functions.

This matters because the dominant narrative about cannabis and the brain comes almost entirely from adolescent research, where the developing brain faces genuine risks from heavy use. The over-40 population is different. These are adults who often use cannabis for sleep, chronic pain, or stress management -- and their brain scans tell a different story than the one we have been told.

Cannabis vs. Alcohol: The Brain Aging Comparison Nobody Wants to Have

The Colorado findings become even more striking when placed next to decades of alcohol research.

Alcohol's effects on the aging brain are unambiguous and dose-dependent. Even one to two drinks per day are linked to measurable gray matter loss and white matter degradation. A twin study found that moderate-to-heavy drinking was associated with a 57 percent higher dementia risk relative to light-drinking co-twins. Chronic alcohol use causes widespread cortical thinning, hippocampal atrophy, and accelerated cognitive decline.

Cannabis users in the UK Biobank study did not show these shrinkage patterns. In the same age group where alcohol consistently reduces brain volume, cannabis users showed preserved or larger volumes in regions critical for memory and learning.

This is not a claim that cannabis protects the brain while alcohol destroys it. The two substances interact with entirely different biological systems, and the cannabis findings are observational. But the contrast is stark, and it matters for public health conversations that have historically treated alcohol as socially acceptable and cannabis as uniquely dangerous.

Canada's 2025 data showing cannabis sales climbing while alcohol declines may be more than a market trend. If the brain science continues to point in this direction, the cultural shift could be driven by biology as much as preference.

The Alzheimer's Connection

Separate research from UT Health San Antonio adds another dimension. In preclinical models, low-dose THC demonstrated a capacity to help clear beta-amyloid plaques -- the protein deposits that are a hallmark of Alzheimer's disease. The challenge is that THC can also trigger localized inflammation in the brain.

The San Antonio team discovered that pairing low-dose THC with celecoxib, an anti-inflammatory medication already approved by the FDA, reduced the inflammatory response while preserving the plaque-clearing effect. Because both substances are already FDA-approved, this "synergy approach" is considered a high-priority target for human clinical trials.

This is preclinical. It has not been tested in humans at scale. But combined with the UK Biobank findings showing preserved hippocampal volume in older cannabis users, it opens a research pathway that could change how we think about neurodegeneration.

Cannabis and Migraines: The First Real Clinical Trial



While the brain aging study reshapes long-term thinking, a landmark clinical trial published in February 2026 in the journal Headache provides immediate clinical evidence for cannabis and migraines.

This was the first randomized, double-blind, placebo-controlled trial testing cannabis for acute migraine treatment. Researchers at UC San Diego enrolled 92 participants who treated 247 separate migraine attacks with four different treatments: THC-dominant cannabis, CBD-dominant cannabis, a THC/CBD combination, and placebo.

The results were decisive. The THC/CBD combination achieved pain relief in 67.2 percent of patients at two hours, compared to 46.6 percent for placebo. Pain freedom was 34.5 percent versus 15.5 percent. Most bothersome symptom freedom was 60.3 percent versus 34.5 percent. The combination also showed sustained pain freedom at 24 hours and sustained symptom freedom at 24 and 48 hours.

Here is what makes these results remarkable: the THC/CBD combination outperformed not just placebo, but THC alone and CBD alone. Neither THC-dominant nor CBD-dominant cannabis was significantly better than placebo for pain freedom at two hours. It was the combination that worked.

The researchers used concentrations of 6 percent THC and 11 percent CBD -- significantly lower than what most dispensaries sell. Lead researcher Dr. Nathaniel Schuster noted that "even a single puff might be enough to provide relief" with commercially available products, and that combining CBD with THC moderates the psychoactive effects, meaning patients feel less high while getting more migraine relief.

For the approximately 39 million Americans who suffer from migraines, this trial provides the kind of evidence that doctors need to have informed conversations with their patients. There were no serious adverse events across any treatment group.